Metformin Induces MeCP2 in the Hippocampus of Male Mice with Sex-Specific and Brain-Region-Dependent Molecular Impact
Abstract
:1. Introduction
2. Materials and Methods
2.1. Ethical Statement
2.2. In Vivo Treatments in Mice and Experimental Design
2.3. Protein Extraction, Western Blot Experiments, and Statistical Analysis
2.4. Antibodies
3. Results
3.1. Metformin Treatment Leads to Sex-Dependent Change in Phosphorylated RPS6 in the Liver, without Affecting the Level of Unphosphorylated RPS6
3.2. Metformin Induces MeCP2 in the Hippocampus of Male Mice, While Inhibiting pre-proBDNF and proBDNF in Female Mice
3.3. The Impact of Metformin on the MeCP2, BDNF, and RPS6 in the Cerebellum and Thalamus
3.4. The Molecular Impact of Metformin in the Murine Frontal Cortex
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Amir, R.E.; Van den Veyver, I.B.; Wan, M.; Tran, C.Q.; Francke, U.; Zoghbi, H.Y. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 1999, 23, 185–188. [Google Scholar] [CrossRef] [PubMed]
- Pejhan, S.; Rastegar, M. Role of DNA Methyl-CpG-Binding Protein MeCP2 in Rett Syndrome Pathobiology and Mechanism of Disease. Biomolecules 2021, 11, 75. [Google Scholar] [CrossRef] [PubMed]
- Long, S.W.; Ooi, J.Y.Y.; Yau, P.M.; Jones, P.L. A brain-derived MeCP2 complex supports a role for MeCP2 in RNA processing. Biosci. Rep. 2011, 31, 333–343. [Google Scholar] [CrossRef] [PubMed]
- Li, Y.; Wang, H.; Muffat, J.; Cheng, A.W.; Orlando, D.A.; Lovén, J.; Kwok, S.-M.; Feldman, D.A.; Bateup, H.S.; Gao, Q.; et al. Global transcriptional and translational repression in human-embryonic-stem-cell-derived Rett syndrome neurons. Cell Stem Cell 2013, 13, 446–458. [Google Scholar] [CrossRef] [PubMed]
- Buist, M.; El Tobgy, N.; Shevkoplyas, D.; Genung, M.; Sher, A.A.; Pejhan, S.; Rastegar, M. Differential Sensitivity of the Protein Translation Initiation Machinery and mTOR Signaling to. Cells 2022, 11, 1442. [Google Scholar] [CrossRef] [PubMed]
- Siqueira, E.; Kim, B.H.; Reser, L.; Chow, R.; Delaney, K.; Esteller, M.; Ross, M.M.; Shabanowitz, J.; Hunt, D.F.; Guil, S.; et al. Analysis of the interplay between MeCP2 and histone H1 during in vitro differentiation of human ReNCell neural progenitor cells. Epigenetics 2023, 18, 2276425. [Google Scholar] [CrossRef] [PubMed]
- Rastegar, M.; Davie, J.R. MeCP2 is the protector of epigenome integrity, membrane-less nuclear architecture, and stability of chromatin assembly. Epigenomics 2023, 15, 1027–1031. [Google Scholar] [CrossRef] [PubMed]
- Pejhan, S.; Del Bigio, M.R.; Rastegar, M. The MeCP2E1/E2-BDNF-miR132 Homeostasis Regulatory Network is Region-Dependent in the Human Brain and Is Impaired in Rett Syndrome Patients. Front. Cell Dev. Biol. 2020, 8, 763. [Google Scholar] [CrossRef] [PubMed]
- Rasmi, Y.; Shokati, A.; Hassan, A.; Aziz, S.G.-G.; Bastani, S.; Jalali, L.; Moradi, F.; Alipour, S. The role of DNA methylation in progression of neurological disorders and neurodegenerative diseases as well as the prospect of using DNA methylation inhibitors as therapeutic agents for such disorders. IBRO Neurosci. Rep. 2023, 14, 28–37. [Google Scholar] [CrossRef]
- Kyle, S.M.; Vashi, N.; Justice, M.J. Rett syndrome: A neurological disorder with metabolic components. Open Biol. 2018, 8, 170216. [Google Scholar] [CrossRef]
- Zuliani, I.; Urbinati, C.; Valenti, D.; Quattrini, M.C.; Medici, V.; Cosentino, L.; Pietraforte, D.; Di Domenico, F.; Perluigi, M.; Vacca, R.A.; et al. The Anti-Diabetic Drug Metformin Rescues Aberrant Mitochondrial Activity and Restrains Oxidative Stress in a Female Mouse Model of Rett Syndrome. J. Clin. Med. 2020, 9, 1669. [Google Scholar] [CrossRef]
- Buist, M.; Fuss, D.; Rastegar, M. Transcriptional Regulation of MECP2E1-E2 Isoforms and BDNF by Metformin and Simvastatin through Analyzing Nascent RNA Synthesis in a Human Brain Cell Line. Biomolecules 2021, 11, 1253. [Google Scholar] [CrossRef]
- Li, N.; Zhou, T.; Fei, E. Actions of Metformin in the Brain: A New Perspective of Metformin Treatments in Related Neurological Disorders. Int. J. Mol. Sci. 2022, 23, 8281. [Google Scholar] [CrossRef]
- Biag, H.M.B.; Potter, L.A.; Wilkins, V.; Afzal, S.; Rosvall, A.; Salcedo-Arellano, M.J.; Rajaratnam, A.; Manzano-Nunez, R.; Schneider, A.; Tassone, F.; et al. Metformin treatment in young children with fragile X syndrome. Mol. Genet. Genom. Med. 2019, 7, e956. [Google Scholar] [CrossRef] [PubMed]
- Garfunkel, D.; Anagnostou, E.A.; Aman, M.G.; Handen, B.L.; Sanders, K.B.; Macklin, E.A.; Chan, J.; Veenstra-VanderWeele, J. Pharmacogenetics of Metformin for Medication-Induced Weight Gain in Autism Spectrum Disorder. J. Child Adolesc. Psychopharmacol. 2019, 29, 448–455. [Google Scholar] [CrossRef]
- Gantois, I.; Khoutorsky, A.; Popic, J.; Aguilar-Valles, A.; Freemantle, E.; Cao, R.; Sharma, V.; Pooters, T.; Nagpal, A.; Skalecka, A.; et al. Metformin ameliorates core deficits in a mouse model of fragile X syndrome. Nat. Med. 2017, 23, 674–677. [Google Scholar] [CrossRef]
- Olson, C.O.; Zachariah, R.M.; Ezeonwuka, C.D.; Liyanage, V.R.; Rastegar, M. Brain region-specific expression of MeCP2 isoforms correlates with DNA methylation within Mecp2 regulatory elements. PLoS ONE 2014, 9, e90645. [Google Scholar] [CrossRef]
- Li, D.; Mei, L.; Li, H.; Hu, C.; Zhou, B.; Zhang, K.; Qiao, Z.; Xu, X.; Xu, Q. Brain structural alterations in young girls with Rett syndrome: A voxel-based morphometry and tract-based spatial statistics study. Front. Neuroinformatics 2022, 16, 962197. [Google Scholar] [CrossRef] [PubMed]
- Xu, F.X.; Wang, X.T.; Cai, X.Y.; Liu, J.Y.; Guo, J.W.; Yang, F.; Chen, W.; Schonewille, M.; De Zeeuw, C.; Zhou, L.; et al. Purkinje-cell-specific MeCP2 deficiency leads to motor deficits and autistic-like behavior due to aberrations in PTP1B-TrkB-SK signaling. Cell Rep. 2023, 42, 113559. [Google Scholar] [CrossRef] [PubMed]
- Yagasaki, Y.; Miyoshi, G.; Miyata, M. Experience-dependent MeCP2 expression in the excitatory cells of mouse visual thalamus. PLoS ONE 2018, 13, e0198268. [Google Scholar] [CrossRef]
- Asgarihafshejani, A.; Raveendran, V.A.; Pressey, J.C.; Woodin, M.A. LTP is Absent in the CA1 Region of the Hippocampus of Male and Female Rett Syndrome Mouse Models. Neuroscience 2023, 537, 189–204. [Google Scholar] [CrossRef]
- Zachariah, R.M.; Olson, C.O.; Ezeonwuka, C.; Rastegar, M. Novel MeCP2 isoform-specific antibody reveals the endogenous MeCP2E1 expression in murine brain, primary neurons and astrocytes. PLoS ONE 2012, 7, e49763. [Google Scholar] [CrossRef] [PubMed]
- Olson, C.O.; Pejhan, S.; Kroft, D.; Sheikholeslami, K.; Fuss, D.; Buist, M.; Ali Sher, A.; Del Bigio, M.R.; Sztainberg, Y.; Siu, V.M.; et al. MECP2 Mutation Interrupts Nucleolin-mTOR-P70S6K Signaling in Rett Syndrome Patients. Front. Genet. 2018, 9, 635. [Google Scholar] [CrossRef] [PubMed]
- Sheikholeslami, K.; Sher, A.A.; Lockman, S.; Kroft, D.; Ganjibakhsh, M.; Nejati-Koshki, K.; Shojaei, S.; Ghavami, S.; Rastegar, M. Simvastatin Induces Apoptosis in Medulloblastoma Brain Tumor Cells via Mevalonate Cascade Prenylation Substrates. Cancers 2019, 11, 994. [Google Scholar] [CrossRef]
- Song, A.; Zhang, C.; Meng, X. Mechanism and application of metformin in kidney diseases: An update. Biomed. Pharmacother. 2021, 138, 111454. [Google Scholar] [CrossRef]
- Vitali, E.; Boemi, I.; Tarantola, G.; Piccini, S.; Zerbi, A.; Veronesi, G.; Baldelli, R.; Mazziotti, G.; Smiroldo, V.; Lavezzi, E.; et al. Metformin and Everolimus: A Promising Combination for Neuroendocrine Tumors Treatment. Cancers 2020, 12, 2143. [Google Scholar] [CrossRef]
- Biever, A.; Valjent, E.; Puighermanal, E. Ribosomal Protein S6 Phosphorylation in the Nervous System: From Regulation to Function. Front. Mol. Neurosci. 2015, 8, 75. [Google Scholar] [CrossRef]
- Poll, S.; Fuhrmann, M. O-LM interneurons: Gatekeepers of pyramidal neuron activity in the hippocampus. Neuron 2022, 110, 1606–1608. [Google Scholar] [CrossRef] [PubMed]
- Palmieri, M.; Pozzer, D.; Landsberger, N. Advanced genetic therapies for the treatment of Rett syndrome: State of the art and future perspectives. Front. Neurosci. 2023, 17, 1172805. [Google Scholar] [CrossRef]
- Zhang, Z.W.; Zak, J.D.; Liu, H. MeCP2 is required for normal development of GABAergic circuits in the thalamus. J. Neurophysiol. 2010, 103, 2470–2481. [Google Scholar] [CrossRef]
- Carter, J.; Lanham, D.; Pham, D.; Bibat, G.; Naidu, S.; Kaufmann, W. Selective cerebral volume reduction in Rett syndrome: A multiple-approach MR imaging study. AJNR Am. J. Neuroradiol. 2008, 29, 436–441. [Google Scholar] [CrossRef] [PubMed]
- Pejhan, S.; Siu, V.M.; Ang, L.C.; Del Bigio, M.R.; Rastegar, M. Differential brain region-specific expression of MeCP2 and BDNF in Rett Syndrome patients: A distinct grey-white matter variation. Neuropathol. Appl. Neurobiol. 2020, 46, 735–750. [Google Scholar] [CrossRef] [PubMed]
- Neul, J.L.; Percy, A.K.; Benke, T.A.; Berry-Kravis, E.M.; Glaze, D.G.; Marsh, E.D.; Lin, T.; Stankovic, S.; Bishop, K.M.; Youakim, J.M. Trofinetide for the treatment of Rett syndrome: A randomized phase 3 study. Nat. Med. 2023, 29, 1468–1475. [Google Scholar] [CrossRef] [PubMed]
- Villemagne, P.M.; Naidu, S.; Villemagne, V.L.; Yaster, M.; Wagner, H.N.; Harris, J.C.; Moser, H.W.; Johnston, M.V.; Dannals, R.F.; Wong, D.F. Brain glucose metabolism in Rett Syndrome. Pediatr. Neurol. 2002, 27, 117–122. [Google Scholar] [CrossRef] [PubMed]
- Golubiani, G.; Lagani, V.; Solomonia, R.; Müller, M. Metabolomic Fingerprint of Mecp2-Deficient Mouse Cortex: Evidence for a Pronounced Multi-Facetted Metabolic Component in Rett Syndrome. Cells 2021, 10, 2494. [Google Scholar] [CrossRef] [PubMed]
- Foretz, M.; Guigas, B.; Bertrand, L.; Pollak, M.; Viollet, B. Metformin: From mechanisms of action to therapies. Cell Metab. 2014, 20, 953–966. [Google Scholar] [CrossRef] [PubMed]
- Lv, Z.; Guo, Y. Metformin and Its Benefits for Various Diseases. Front. Endocrinol. 2020, 11, 191. [Google Scholar] [CrossRef] [PubMed]
- Liu, D.; Nanclares, C.; Simbriger, K.; Fang, K.; Lorsung, E.; Le, N.; Amorim, I.S.; Chalkiadaki, K.; Pathak, S.S.; Li, J.; et al. Autistic-like behavior and cerebellar dysfunction in Bmal1 mutant mice ameliorated by mTORC1 inhibition. Mol. Psychiatry 2023, 28, 3727–3738. [Google Scholar] [PubMed]
- Sanchis, A.; García-Gimeno, M.A.; Cañada-Martínez, A.J.; Sequedo, M.D.; Millán, J.M.; Sanz, P.; Vazquez-Manrique, R.P. Metformin treatment reduces motor and neuropsychiatric phenotypes in the zQ175 mouse model of Huntington disease. Exp. Mol. Med. 2019, 51, 1–16. [Google Scholar] [CrossRef]
- Yan, Q.; Han, C.; Wang, G.; Waddington, J.L.; Zheng, L.; Zhen, X. Activation of AMPK/mTORC1-Mediated Autophagy by Metformin Reverses Clk1 Deficiency-Sensitized Dopaminergic Neuronal Death. Mol. Pharmacol. 2017, 92, 640–652. [Google Scholar] [CrossRef]
- Wang, Y.; Zhao, J.; Guo, F.-L.; Gao, X.; Xie, X.; Liu, S.; Yang, X.; Yang, X.; Zhang, L.; Ye, Y.; et al. Metformin Ameliorates Synaptic Defects in a Mouse Model of AD by Inhibiting Cdk5 Activity. Front. Cell Neurosci. 2020, 14, 170. [Google Scholar] [CrossRef] [PubMed]
- Urbinati, C.; Lanzillotta, C.; Cosentino, L.; Valenti, D.; Quattrini, M.C.; Di Crescenzo, L.; Prestia, F.; Pietraforte, D.; Perluigi, M.; Di Domenico, F.; et al. Chronic treatment with the anti-diabetic drug metformin rescues impaired brain mitochondrial activity and selectively ameliorates defective cognitive flexibility in a female mouse model of Rett syndrome. Neuropharmacology 2023, 224, 109350. [Google Scholar] [CrossRef] [PubMed]
- Wang, J.; Gallagher, D.; DeVito, L.M.; Cancino, G.I.; Tsui, D.; He, L.; Keller, G.M.; Frankland, P.W.; Kaplan, D.R.; Miller, F.D. Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation. Cell Stem Cell 2012, 11, 23–35. [Google Scholar] [CrossRef] [PubMed]
- Howell, J.J.; Hellberg, K.; Turner, M.; Talbott, G.; Kolar, M.J.; Ross, D.S.; Hoxhaj, G.; Saghatelian, A.; Shaw, R.J.; Manning, B.D. Metformin Inhibits Hepatic mTORC1 Signaling via Dose-Dependent Mechanisms Involving AMPK and the TSC Complex. Cell Metab. 2017, 25, 463–471. [Google Scholar] [CrossRef] [PubMed]
- Ruddy, R.M.; Adams, K.V.; Morshead, C.M. Age- and sex-dependent effects of metformin on neural precursor cells and cognitive recovery in a model of neonatal stroke. Sci. Adv. 2019, 5, eaax1912. [Google Scholar] [CrossRef] [PubMed]
- Gilbert, E.A.B.; Livingston, J.; Garcia-Flores, E.; Kehtari, T.; Morshead, C.M. Metformin Improves Functional Outcomes, Activates Neural Precursor Cells, and Modulates Microglia in a Sex-Dependent Manner After Spinal Cord Injury. Stem Cells Transl. Med. 2023, 12, 415–428. [Google Scholar] [CrossRef] [PubMed]
- Raparelli, V.; Elharram, M.; Moura, C.S.; Abrahamowicz, M.; Bernatsky, S.; Behlouli, H.; Pilote, L. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus. J. Am. Heart Assoc. 2020, 9, e012940. [Google Scholar] [CrossRef] [PubMed]
- Lashen, H. Role of metformin in the management of polycystic ovary syndrome. Ther. Adv. Endocrinol. Metab. 2010, 1, 117–128. [Google Scholar] [CrossRef] [PubMed]
- Singh, A.K.; Singh, R. Metformin in gestational diabetes: An emerging contender. Indian J. Endocrinol. Metab. 2015, 19, 236–244. [Google Scholar] [CrossRef]
- de Vries, S.T.; Denig, P.; Ekhart, C.; Mol, P.G.; van Puijenbroek, E.P. Sex Differences in Adverse Drug Reactions of Metformin: A Longitudinal Survey Study. Drug Saf. 2020, 43, 489–495. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Arezoumand, K.S.; Roberts, C.-T.; Rastegar, M. Metformin Induces MeCP2 in the Hippocampus of Male Mice with Sex-Specific and Brain-Region-Dependent Molecular Impact. Biomolecules 2024, 14, 505. https://doi.org/10.3390/biom14040505
Arezoumand KS, Roberts C-T, Rastegar M. Metformin Induces MeCP2 in the Hippocampus of Male Mice with Sex-Specific and Brain-Region-Dependent Molecular Impact. Biomolecules. 2024; 14(4):505. https://doi.org/10.3390/biom14040505
Chicago/Turabian StyleArezoumand, Khatereh Saei, Chris-Tiann Roberts, and Mojgan Rastegar. 2024. "Metformin Induces MeCP2 in the Hippocampus of Male Mice with Sex-Specific and Brain-Region-Dependent Molecular Impact" Biomolecules 14, no. 4: 505. https://doi.org/10.3390/biom14040505